Tectonic Therapeutic (TECX)

The company’s discovery engine, known as GEODe, is built to help identify and engineer biologics that can act on GPCRs, including targets that have historically been difficult to drug. Tectonic applies this platform to diseases where existing treatment options are limited and where changing receptor signalling could alter the course of illness rather than only manage symptoms.

Its pipeline includes TX000045, a programme being advanced for Group 2 pulmonary hypertension, a form of pulmonary hypertension associated with left heart disease. Tectonic is also developing TX2100, a GPCR antagonist programme for hereditary hemorrhagic telangiectasia, a genetic vascular disorder that can cause abnormal blood vessel formation and recurrent bleeding. The company also identifies fibrosis as an area of interest.

As a publicly listed biotech, Tectonic’s value is closely tied to progress in preclinical and clinical development, the strength of its GPCR biology, and the ability of its platform to produce differentiated drug candidates. Investors typically assess the company through pipeline milestones, safety and efficacy data, regulatory progress, financing capacity, and the broader market appetite for innovative therapies targeting high-unmet-need diseases.